Funding analysts at StockNews.com started protection on shares of GlycoMimetics (NASDAQ:GLYC – Get Rating) in a analysis be aware issued to traders on Tuesday. The brokerage set a “maintain” ranking on the biotechnology firm’s inventory.
GlycoMimetics Inventory Efficiency
GLYC opened at $2.27 on Tuesday. GlycoMimetics has a 52-week low of $0.51 and a 52-week excessive of $2.51. The inventory has a market capitalization of $119.00 million, a PE ratio of -2.23 and a beta of two.42. The inventory’s 50 day shifting common value is $1.59 and its 200-day shifting common value is $1.01.
Insiders Place Their Bets
In different GlycoMimetics information, insider Edwin Rock bought 100,000 shares of the inventory in a transaction dated Monday, November 14th. The shares had been bought at a mean price of $1.43 per share, with a complete worth of $143,000.00. Following the completion of the acquisition, the insider now instantly owns 100,000 shares within the firm, valued at roughly $143,000. The transaction was disclosed in a submitting with the SEC, which is out there at the SEC website. Company insiders personal 8.00% of the corporate’s inventory.
Institutional Buying and selling of GlycoMimetics
Plenty of hedge funds and different institutional traders have lately purchased and bought shares of GLYC. Acadian Asset Administration LLC grew its place in shares of GlycoMimetics by 2.0% in the course of the first quarter. Acadian Asset Administration LLC now owns 1,990,087 shares of the biotechnology firm’s inventory price $2,267,000 after buying a further 39,001 shares within the final quarter. Vanguard Group Inc. lifted its stake in shares of GlycoMimetics by 1.8% within the third quarter. Vanguard Group Inc. now owns 1,879,412 shares of the biotechnology firm’s inventory valued at $1,037,000 after buying a further 32,650 shares over the last quarter. Renaissance Applied sciences LLC lifted its stake in shares of GlycoMimetics by 20.4% within the 2nd quarter. Renaissance Applied sciences LLC now owns 566,400 shares of the biotechnology firm’s inventory valued at $339,000 after buying a further 95,800 shares over the last quarter. Lastly, Millennium Administration LLC lifted its stake in shares of GlycoMimetics by 7.5% within the 2nd quarter. Millennium Administration LLC now owns 434,655 shares of the biotechnology firm’s inventory valued at $260,000 after buying a further 30,466 shares over the last quarter. Hedge funds and different institutional traders personal 49.50% of the corporate’s inventory.
GlycoMimetics, Inc, a clinical-stage biotechnology firm, focuses on the invention and growth of novel glycomimetic medication to deal with unmet medical wants ensuing from ailments in america. It’s growing uproleselan, an E-selectin inhibitor, which is utilized in mixture with chemotherapy to deal with acute myeloid leukemia (AML), in addition to in part 3 trial to deal with relapsed/refractory AML.
This prompt information alert was generated by narrative science expertise and monetary knowledge from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you take into account GlycoMimetics, you will wish to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and GlycoMimetics wasn’t on the listing.
Whereas GlycoMimetics at the moment has a “Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.